118 related articles for article (PubMed ID: 4027532)
1. The value of staging and serial follow-up investigations in patients with completely resected, primary, cutaneous malignant melanoma.
Kersey PA; Iscoe NA; Gapski JA; Osoba D; From L; DeBoer G; Quirt IC
Br J Surg; 1985 Aug; 72(8):614-7. PubMed ID: 4027532
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of staging investigations in patients with clinical stage I malignant melanoma.
Iscoe N; Kersey P; Gapski J; Osoba D; From L; DeBoer G; Quirt I
Plast Reconstr Surg; 1987 Aug; 80(2):233-9. PubMed ID: 3602173
[TBL] [Abstract][Full Text] [Related]
3. Does staging computered tomography change management in thick malignant melanoma?
Sawyer A; McGoldrick RB; Mackey SP; Allan R; Powell B
J Plast Reconstr Aesthet Surg; 2009 Apr; 62(4):453-6. PubMed ID: 18468970
[TBL] [Abstract][Full Text] [Related]
4. Findings of computed tomography in stage IIB and IIC melanoma: a six-year retrospective study in the South-East of Scotland.
Orfaniotis G; Mennie JC; Fairbairn N; Butterworth M
J Plast Reconstr Aesthet Surg; 2012 Sep; 65(9):1216-9. PubMed ID: 22525255
[TBL] [Abstract][Full Text] [Related]
5. Surveillance strategies in the follow-up of melanoma patients: too much or not enough?
Kurtz J; Beasley GM; Agnese D; Kendra K; Olencki TE; Terando A; Howard JH
J Surg Res; 2017 Jun; 214():32-37. PubMed ID: 28624057
[TBL] [Abstract][Full Text] [Related]
6. Metastatic disease in patients with newly diagnosed malignant melanoma.
Zartman GM; Thomas MR; Robinson WA
J Surg Oncol; 1987 Jul; 35(3):163-4. PubMed ID: 3599990
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of imaging strategy for an intensive follow-up of patients with American Joint Committee on Cancer stage IIB, IIC and III malignant melanoma.
Podlipnik S; Moreno-Ramírez D; Carrera C; Barreiro A; Manubens E; Ferrandiz-Pulido L; Sánchez M; Vidal-Sicart S; Malvehy J; Puig S
Br J Dermatol; 2019 May; 180(5):1190-1197. PubMed ID: 29876940
[TBL] [Abstract][Full Text] [Related]
8. [Malignant melanoma: which examinations are useful in staging and follow-up?].
Goerz G; Schulte-Beerbühl R; Roder K; Schoppe WD; Münchhoff C; Jungblut RM
Dtsch Med Wochenschr; 1986 Aug; 111(33):1230-3. PubMed ID: 3527640
[TBL] [Abstract][Full Text] [Related]
9. FDG PET in early stage cutaneous malignant melanoma.
McIvor J; Siew T; Campbell A; McCarthy M
J Med Imaging Radiat Oncol; 2014 Apr; 58(2):149-54; quiz 266. PubMed ID: 24690243
[TBL] [Abstract][Full Text] [Related]
10. Verification of musculoskeletal FDG-PET-CT findings performed for melanoma staging.
Mansour AA; Kelley MC; Hatmaker AR; Holt GE; Schwartz HS
Ann Surg Oncol; 2010 Apr; 17(4):1144-51. PubMed ID: 19967460
[TBL] [Abstract][Full Text] [Related]
11. Costs of the detection of metastases and follow-up examinations in cutaneous melanoma.
Leiter U; Marghoob AA; Lasithiotakis K; Eigentler TK; Meier F; Meisner C; Garbe C
Melanoma Res; 2009 Feb; 19(1):50-7. PubMed ID: 19430406
[TBL] [Abstract][Full Text] [Related]
12. Classification and staging of melanoma.
Gershenwald JE; Buzaid AC; Ross MI
Clin Lab Med; 2000 Dec; 20(4):785-815. PubMed ID: 11221515
[TBL] [Abstract][Full Text] [Related]
13. The role of positron emission tomography with computed tomography in the follow-up of asymptomatic cutaneous malignant melanoma patients with a high risk of disease recurrence.
Abbott RA; Acland KM; Harries M; O'Doherty M
Melanoma Res; 2011 Oct; 21(5):446-9. PubMed ID: 21849913
[TBL] [Abstract][Full Text] [Related]
14. TRIM study protocol - a prospective randomized multicenter Trial to assess the Role of Imaging during follow-up after radical surgery of stage IIB-C and III cutaneous malignant Melanoma.
Naeser Y; Helgadottir H; Brandberg Y; Hansson J; Bagge RO; Elander NO; Ingvar C; Isaksson K; Flygare P; Nilsson C; Jakobsson F; Del Val Munoz O; Valachis A; Jansson M; Sparring C; Ohlsson L; Dyrke U; Papantoniou D; Sundin A; Ullenhag GJ
BMC Cancer; 2020 Dec; 20(1):1197. PubMed ID: 33287744
[TBL] [Abstract][Full Text] [Related]
15. Radioimmunoscintigraphy in patients with early stage cutaneous malignant melanoma.
Blend MJ; Hyun H; Patel B; Sullivan K; Salk D
J Nucl Med; 1996 Feb; 37(2):252-7. PubMed ID: 8667055
[TBL] [Abstract][Full Text] [Related]
16. [Follow-up for cutaneous melanoma].
Kettelhack C
Ther Umsch; 2008 Jun; 65(6):335-40. PubMed ID: 18622957
[TBL] [Abstract][Full Text] [Related]
17. Clinical relevance of 18F-FDG PET/CT lower-limb imaging in patients with malignant cutaneous melanoma.
Plouznikoff N; Arsenault F
Nucl Med Commun; 2017 Dec; 38(12):1103-1108. PubMed ID: 28885538
[TBL] [Abstract][Full Text] [Related]
18. The significance of imaging examinations during follow-up for malignant melanoma.
Pozsgai M; Németh K; Oláh P; Gyulai R; Lengyel Z
Eur J Dermatol; 2021 Jun; 31(3):357-363. PubMed ID: 34309521
[TBL] [Abstract][Full Text] [Related]
19. 3'-18F-fluoro-3'-deoxy-L-thymidine: a new tracer for staging metastatic melanoma?
Cobben DC; Jager PL; Elsinga PH; Maas B; Suurmeijer AJ; Hoekstra HJ
J Nucl Med; 2003 Dec; 44(12):1927-32. PubMed ID: 14660718
[TBL] [Abstract][Full Text] [Related]
20. Clinical value of including the head and lower extremities in 18F-FDG PET/CT imaging for patients with malignant melanoma.
Niederkohr RD; Rosenberg J; Shabo G; Quon A
Nucl Med Commun; 2007 Sep; 28(9):688-95. PubMed ID: 17667747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
